98%
921
2 minutes
20
Objective: Anorexia nervosa (AN) is associated with hyperactivity, amenorrhea, and brain atrophy. Weight rehabilitation reversed these symptoms, although the underlying pathophysiological mechanisms are mostly unknown. Serum neurofilament light chain (NfL) levels are widely used as a biomarker of neurodegeneration. Based on neuroimaging studies and increased serum NfL levels, we assume that neurodegeneration is a core neuropathological feature in AN patients.
Method: Female mice were given a limited amount of food once a day and had unlimited access to a running wheel until they reached a 25% weight reduction, which was maintained for 2 weeks to mimic chronic starvation. This was followed by 3 weeks of refeeding. Running activity was measured by wheel sensors, while amenorrhea was determined by analyzing vaginal smears. Brain sections were used to investigate brain volumes. NfL levels were determined using a NF-light assay. Behavioral tests such as forced swim and elevated plus maze assessed behavioral changes. Immunohistochemistry was used to quantify the density of microglia, while their morphological analysis was performed using Neurolucida 360.
Results: Chronic starvation led to AN-related symptoms of hyperactivity and amenorrhea. The decreased cerebral cortex, hippocampal, and corpus callosum volumes were paralleled by increased NfL levels after chronic starvation. A behavioral association was reduced anxiety-like behavior after chronic starvation. Starvation induced decreased microglial density, increased soma area, and prolonged microglial processes.
Discussion: Chronic starvation led to an increase in NfL levels and changed microglial morphology in a mouse model of AN, suggesting that neuronal pathophysiology may contribute to the disease.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC12138848 | PMC |
http://dx.doi.org/10.1002/eat.24423 | DOI Listing |
Geroscience
September 2025
Department of Biological Sciences, College of Natural Sciences, Kangwon National University, Kangwon, 24341, Republic of Korea.
Alzheimer's disease (AD) represents a growing global health burden, underscoring the urgent need for reliable diagnostic and prognostic biomarkers. Although several disease-modifying treatments have recently become available, their effects remain limited, as they primarily delay rather than halt disease progression. Thus, the early and accurate identification of individuals at elevated risk for conversion to AD dementia is crucial to maximize the effectiveness of these therapies and to facilitate timely intervention strategies.
View Article and Find Full Text PDFAnn Clin Transl Neurol
September 2025
Department of Pediatrics, National Taiwan University Hospital, Taipei, Taiwan.
Objective: Neuroinflammation driven by extracellular copper contributes to neuronal damage in Wilson's disease (WD). This study investigated the relationship between brain metal burden and peripheral neuroinflammation markers in WD.
Methods: We conducted a cross-sectional study involving 89 participants, including patients with WD (n = 63), asymptomatic ATP7B heterozygous carriers (n = 12), and age/sex-matched controls (n = 14).
J Prev Alzheimers Dis
September 2025
Stanford Neuroscience Health Center, Stanford University, Palo Alto CA USA.
Background: AR1001 is a phosphodiesterase-5 inhibitor that produces improved cognitive performance and reduces amyloid-β and phosphorylated tau burdens in preclinical models of Alzheimer's disease (AD).
Objectives: To evaluate the safety and efficacy of AR1001 in participants with mild-to-moderate Alzheimer's disease (AD).
Design: Randomized, double-blind, placebo-controlled phase 2 trial conducted at 21 sites in the United States.
JAMA Netw Open
September 2025
Department of Neurosciences, University of California, San Diego, La Jolla.
Importance: Subjective cognitive decline (SCD) may be an early indicator of Alzheimer disease and related dementias (ADRD), yet its association with plasma biomarkers remains unclear among middle-aged and older adults (aged 50-86 years).
Objective: To examine associations between plasma biomarkers of amyloid, tau, neuroaxonal damage, and glial activation with SCD in a heterogeneous cohort of Hispanic and/or Latino adults.
Design, Setting, And Participants: This cross-sectional study used survey-weighted data from the Study of Latinos-Investigation of Neurocognitive Aging, an ancillary study of the Hispanic Community Health Study/Study of Latinos.
Oncol Ther
September 2025
Department of Infectious Diseases, Nord Franche-Comté Hospital, Belfort, France.
This is the first documented case of recurrent, severe, and highly inflammatory panmyelitis induced by pembrolizumab. A 41-year-old woman with nodular melanoma developed tetraparesis after three cycles of pembrolizumab treatment. Spinal magnetic resonance imaging (MRI) revealed extensive longitudinal panmyelitis, and cerebrospinal fluid analysis showed markedly elevated cell counts (3900/mm).
View Article and Find Full Text PDF